[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephropathy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,41,65,101,144,175,203,233,261,289],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100552138","early-phase-1-an-exploratory-clinical-study-of-anti-cd19-car-nk-cell-kn5501-in-the-treatment-of-relapsedrefractory-immune-nephropathy-100552138",false,"NCT06469190","An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed\u002FRefractory Immune Nephropathy","An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor NK Cell Injections (KN5501) in the Treatment of Relapsed\u002FRefractory Immune Nephropathy","Common Inclusion Criteria:\n\n1. Age: ≥ 18 years old and ≤ 70 years old, male or female;\n2. Positive CD19 expression in peripheral blood B cells as determined by flow cytometry;\n3. The functions of important organs meet the following requirements:\n\n   1. Bone marrow hematopoietic function: a. White blood cell count ≥ 3 x 10\\^9\u002FL b. Neutrophil count ≥ 1 x 10\\^9\u002FL (no colony-stimulating factor treatment within 2 weeks before examination); c. Hemoglobin ≥60g\u002FL.\n   2. Liver function: ALT ≤ 3 x ULN,AST≤3 x ULN, TBIL≤1.5 x ULN(excluding Gilbert syndrome, total bilirubin ≤ 3.0 x ULN)\n   3. Coagulation function: International standardized ratio (INR) ≤ 1.5 x ULN, prothrombin time (PT) ≤1.5 x ULN.\n   4. Cardiac function: good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥55%.\n4. Female subjects of childbearing potential and male subjects whose partner is a female of childbearing potential are required to use medically approved contraception or abstain from sex for at least 6 months during and at least 6 months after the end of the study treatment period; female subjects of childbearing potential have had a negative serum HCG test within 7 days prior to study enrollment and are not lactating;\n5. Voluntarily participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nCriteria for Recurrent\u002Frefractory primary membranous nephropathy\n\n1. Primary membranous nephropathy diagnosed pathologically by renal biopsy;\n2. Screening period 24-hour urine protein quantification ≥3.5 g;\n3. Individuals who have not achieved partial remission (PR) after more than 6 months of treatment with hormonal and\u002For cytotoxic drugs, immunosuppressive therapy, and\u002For biologics (including but not limited to anti-CD20 monoclonal antibody); or individuals who have relapsed again after achieving complete remission\u002Fpartial remission (CR\u002FPR) with treatment (24h urine protein quantification ≥3.5g);\n4. Glomerular filtration rate (eGFR, CKD-EPI formula) ≥45 ml\u002Fmin\u002F1.73m2 during the screening period.\n\nCriteria for Relapsed\u002Frefractory IgA nephropathy\n\n1. Primary IgA nephropathy pathologically confirmed by renal biopsy;\n2. Treated (ACEI\u002FARB analogs) for at least 3 months;\n3. Treatment with hormonal and\u002For cytotoxic drugs, immunosuppressive therapy, and\u002For biologics (including, but not limited to anti-CD20 monoclonal antibody) for more than 6 months, 24-hour urine protein quantification ≥ 1.0 g; or rapid progression of renal function (≥ 50% decrease in eGFR within 3 months); or relapse after treatment to achieve complete remission\u002Fpartial remission (CR\u002FPR) (24-hour urine protein quantification ≥ 1.0 g);\n4. Glomerular filtration rate (eGFR, CKD-EPI formula) ≥30 ml\u002Fmin\u002F1.73m2 during the screening period.\n\nCriteria for Relapsed\u002Frefractory ANCA-associated vasculitis\n\n1. Meets 2022 ACR\u002FEULAR diagnostic criteria for ANCA vasculitis, including microscopic polyangiitis, granulomatous polyangiitis, eosinophilic granulomatous polyangiitis;\n2. Positive ANCA related antibodies (MPO-ANCA or PR3-ANCA positive);\n3. Renal biopsy pathology consistent with renal damage in ANCA-associated vasculitis;\n4. The Birmingham Vasculitis Activity Scale (BVAS) is ≥ 15 points (a total score of 63 points), indicating the activity of the vasculitis condition;\n5. BVAS score includes at least 2 abnormalities in the renal program;\n6. Definition of relapse\u002Frefractory : ineffective conventional treatment or relapse of disease activity after remission. Definition of routine treatment: use of glucocorticoids (more than 1 mg\u002Fkg\u002Fd) and cyclophosphamide for ≥3 months, and any of the following immunomodulatory drugs: antimalarial drugs, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, as well as biological agents such as rituximab and belimumab;\n7. Glomerular filtration rate (eGFR, CKD-EPI formula) ≥15 ml\u002Fmin\u002F1.73m2 during the screening period.\n\nCommon exclusion Criteria:\n\n1. Individuals with known severe allergic reactions, hypersensitivity, contraindication to any medications during the trial (cyclophosphamide, fludarabine, tozumabs), or subjects with a history of severe allergic reactions;\n2. Existence or suspicion of uncontrollable or treatable fungal, bacterial, viral or other infections;\n3. Individuals with central nervous system disorders caused by ADs or not caused by ADs (including epilepsy, psychiatric disorders, organic encephalopathy syndromes, cerebrovascular accidents, encephalitis, central nervous system vasculitis);\n4. Individuals with relatively serious heart diseases, such as angina pectoris, myocardial infarction, heart failure, and arrhythmia;\n5. Subjects with congenital immunoglobulin deficiency;\n6. Subjects with malignant tumors (except for non-melanoma skin cancer and in situ cervical, bladder, and breast cancers that have been disease-free for more than 5 years);\n7. Subjects with end-stage renal failure;\n8. Subjects with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and HBV DNA titer in peripheral blood higher than the upper limit of detection; Patients with positive hepatitis C virus (HCV) antibodies and positive peripheral blood HCV RNA; People who are positive for human immunodeficiency virus (HIV) antibodies; Those who have tested positive for syphilis;\n9. Subjects with mental illness and severe cognitive impairment;\n10. Subjects who have received other clinical trial treatment within 3 months;\n11. Pregnant or intending to conceive women;\n12. In the opinion of the investigator, there are other reasons why subjects cannot be included in this study.\n\nExclusion Criteria for Recurrent\u002Frefractory primary membranous nephropathy\n\n1. Secondary membranous nephropathy (e.g., hepatitis B, systemic lupus erythematosus, drug-associated, malignancy-associated, etc.), or in combination with other renal diseases confirmed by renal biopsy;\n2. Type 1 or type 2 diabetes.\n\nExclusion Criteria for Relapsed\u002Frefractory IgA nephropathy\n\n1. Exclude secondary IgA nephropathy, including but not limited to: anaphylactic purpura, ankylosing spondylitis, systemic lupus erythematosus, desiccation syndrome, viral hepatitis, cirrhosis of the liver, rheumatoid arthritis, and mixed connective tissue disease; or in combination with other renal diseases confirmed by renal biopsy;\n2. Crescentic nephritis (pathologic diagnosis of \\>50% crescentic bodies), micrognathic nephropathy with IgA deposition, and other specific types of pathologic or clinical renal disease.\n\nExclusion Criteria for Relapsed\u002Frefractory ANCA-associated vasculitis\n\n1. Estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin\u002F1.73 m2;\n2. If the patient has alveolar hemorrhage invasive lung ventilation is required, estimated to last longer than the screening period.","ALL","18 Years","70 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19 CAR NK cell injection (KN5501) in patients with immune nephropathy. 36 patients are planned to be enrolled in the dose-escalation trial. The primary endpoints are DLT and TEAEs. The secondary endpoints are the overall response rates (ORR) and disease control rate (DCR)",[27],"Nephropathy","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":32},"2024-06-21",{"date":36,"type":21},"2027-06-20",{"name":38,"class":39},"Changhai Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100271830","improving-renal-complications-in-adolescents-with-type-2-diabetes-through-research-cohort-study-national-icare-study-100271830","NCT02818192","Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)","iCARE","Inclusion Criteria:\n\n* All youth with T2D that do not meet exclusion criteria are eligible for the study.\n\nCriteria for Diagnosis of T2D:\n\n1. Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:\n\n   * Fasting plasma glucose of \\> 7.0 mmol\u002FL or\n   * Random glucose \\> 11.1mmol\u002FL or\n   * 2 hour glucose \\> 11.1 mmol\u002FL after a standard oral glucose tolerance test (75g) or\n   * Hemoglobin A1c value ≥ 6.5%\n2. Distinguishing T2D from type 1 diabetes (T1D) will be based on clinical risk factors including:\n\n   * Presence of overweight\u002Fobesity,\n   * Other evidence of insulin resistance (acanthosis nigricans)\n   * Family history of type 2 diabetes (1st degree relative)\n   * Intrauterine exposure to hyperglycemia,\n   * Family heritage from a high-risk ethnic group (Indigenous, Hispanic, South Asian, Asian or African descent)\n   * Absence of diabetes associated auto-antibodies\n   * HNF-1 alpha heterozygote or homozygote\n\nExclusion Criteria:\n\n1. Diabetes secondary to medication use or surgery\n2. Antibodies suggestive of type 1 diabetes\n3. Current treatment with oral steroids or immunosuppressive agents as they may interfere with cortisol assessment and inflammatory markers\n4. Ever cancer\n5. Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohns disease)\n6. Patient and or caregiver unable or unwilling to provide voluntary informed assent\u002Fconsent","10 Years",{"count":50,"type":21},500,"OBSERVATIONAL","The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include:\n\n1. Characterize the primary BPS risk factors associated with prevalent and progressive albuminuria in youth with T2D.\n2. Determine individual, family and community level factors that influence biological and psychological risk factors and behaviors (adherence) that could be modified to protect against prevalent and progressive albuminuria.\n3. Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.\n\nStudy Hypotheses include:\n\n1. Biological factors (poor glycemic control and systolic ambulatory hypertension), and psychological and social adversity (stress, mental distress and poverty) are significant predictors of prevalent and progressive albuminuria in youth with T2D.\n2. Community and family support will be negatively associated with stress, and a lower risk of both prevalent and progressive albuminuria.\n3. Systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.",[54,55,56,27],"Type 2 Diabetes","Proteinuria","Stress",{"date":58,"type":32},"2026-06-29",{"date":60,"type":32},"2017-01",{"date":62,"type":21},"2027-03",{"name":64,"class":39},"University of Manitoba",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":74,"conditions":75,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100619680","study-of-the-serotype-and-genotype-of-bk-virus-in-kidney-transplant-recipients-and-their-donors-to-identify-individuals-at-risk-of-nephropathy-100619680","NCT07347769","Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy","TYPIK","Inclusion Criteria:\n\n* Kidney transplant patients with a first positive BK virus viral load in urine. - BK virus viral load in urine \\> 3 log copies\u002FmL.\n* More than 3 months post-transplant and less than 2 years post-transplant.\n* Men or women aged 18 years and older.\n* Followed up at Grenoble Alpes University Hospital.\n* Affiliated with social security or beneficiary of such a scheme.\n* Patients who are not opposed to the TYPIK study.\n\nExclusion Criteria:\n\n* Expected renal graft survival is \\\u003C 6 months, estimated by an eGFR \\\u003C 15 mL\u002Fmin\u002F1.73 m² at the time of BKPyV viruria\n* Patients who object to the use of their data and\u002For samples for research purposes\n* Subjects who are excluded from another study\n* Subjects under administrative or judicial supervision",{"count":73,"type":21},100,"The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients. Although BKV reactivation after transplantation is well established, the origin of the replicating virus remains uncertain. Current evidence suggests that BKV detected in recipients may originate either from the transplanted kidney (donor-derived) or from viral reactivation in the recipient. The evaluation of new biomarkers to predict BKV replication are needed.\n\nThis study seeks to address the following key questions:\n\n* Origin of the replicating virus: Is the BKV detected in the recipient identical to the virus originating from the donor kidney?\n* Host immune response and viral genotype: Is there an association between the recipient's immune response and the genotype of the replicating BKV?\n* Differences in immune response according to viral replication profile: Does the immune response differ between patients presenting isolated BKV viruria and those with both viruria and viremia?\n* Can new biomarkers help predict BKV replication and viremia?\n\nPatients will be grouped according to their BKV replication profile:\n\nGroup 1: patients with BKV viruria without viremia Group 2: patients with both BKV viruria and viremia Comparisons between these two groups will help identify whether different viral genotypes or immune responses are associated with systemic dissemination (viremia).\n\nKidney transplant recipients will be included if they present BKV viruria during their post-transplant follow-up. Additional blood samples will be collected during scheduled follow-up visits at the university hospital. These visits are part of routine clinical care, and no extra visits will be required specifically for the study.",[27,76,77,78,79,80,81,82,83],"Opportunistic Viral Infection","Polyoma Virus Nephropathy","BK Nephropathy","BK Viremia; BKV DNAemia","BK Virus Infection","BK Polyomavirus","Immune Response","Neutralizing Antibodies",[85,86,87,88,89,90,91],"TTV","BK polyomavirus","neutralizing antibodies","ELISPOT BKV","genotype","miRNA BKV","urinary chimiokine","2026-05-22",{"date":94,"type":32},"2026-05-27",{"date":96,"type":32},"2026-03-11",{"date":98,"type":21},"2030-09-11",{"name":100,"class":39},"University Hospital, Grenoble",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":111,"conditions":112,"keywords":121,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100580429","studying-the-presence-of-cfrd-complications-with-thoughtful-recruitment-spectrum-100580429","NCT06837181","Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)","SPeCTRuM","Inclusion Criteria:\n\n* Written informed consent (and assent when applicable) obtained from participant or participant's legally authorized representative\n* For Adults: Must be able to consent on one own's behalf (i.e., cannot lack cognitive capacity to consent due to the required patient-reported outcomes)\n* Be willing and able to adhere to the study protocol requirements\n* Age ≥ 12 years at time of enrollment\n* CF diagnosis based on two CF causing mutations and\u002For positive sweat test according to CFF diagnostic criteria\n* CFRD diagnosis ≥ 5 years at time of enrollment\n\nExclusion Criteria:\n\n* History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk to the subject\n* History of transplant\n* Pregnancy reported by participant at time of consent or at any point during active study participation\n\nPulse Wave Velocity Exclusion Criteria:\n\n* Erratic, accelerated or mechanically controlled irregular heart rhythms including arrhythmias\n* Carotid or aortic valve stenosis\n* Peripheral artery disease or leg artery disease\n* Generalized constriction or localized spasm of muscular conduit arteries such as seen immediately after hypothermic cardiopulmonary bypass surgery or accompanying Raynaud's phenomena or intense cold.\n* Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):\n\n  * Pressure reading should not be conducted on a limb where there is intravenous access, arterio-venous shunt, or where circulation is compromised.\n  * Pressure reading should not be conducted on the side of the body that a mastectomy was done.","12 Years",{"count":110,"type":21},200,"This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.\n\nThe overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.",[113,114,115,116,117,27,118,119,120],"Cystic Fibrosis (CF)","Cystic Fibrosis-related Diabetes","Diabetes","Retinopathy","Neuropathy","Blood Pressure","Cardiovascular Risk","Microvascular",[122,123,124,125,126,127,128,115,129,130,131,132,133],"Cystic Fibrosis","CFRD","Cystic Fibrosis-Related Diabetes","Observational","Physical Activity Tracker","Continuous glucose monitoring","CGM","blood pressure","cardiovascular risk","microvascular","diabetes complications","social determinants of health","2026-02-09",{"date":136,"type":32},"2026-02-10",{"date":138,"type":32},"2025-09-18",{"date":140,"type":21},"2028-11-30",{"name":142,"class":39},"Jaeb Center for Health Research",18,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100612660","salivary-replication-of-bk-virus-in-post-kidney-transplant-100612660","NCT07256470","Salivary Replication of BK Virus in Post-kidney Transplant","BKSAL","Inclusion Criteria:\n\n* kidney transplant recipients\n* age ≥ 18 years\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* absence of consent",{"count":73,"type":21},[153],"NA","BK virus infection in kidney transplantation can compromise graft function. Current data suggest that BK virus nephropathy results not only from transmission of virus from the donor but also from reactivation of latent virus in the recipient. However, no study has investigated the possibility of respiratory transmission. This study would provide a better understanding of the pathophysiology of BK virus infection in kidney transplant recipients. The investigators would study viral replication of BK virus in saliva, urine and blood of patients who received a kidney transplant at the Amiens University Hospital. For this, the investigators will collect salivary self-collection on the day of the kidney transplant then at 1, 3, 6, 9 and 12 months as well as a urine and blood sample. The investigators will measure BK viral load in these three samples at different times.",[156,157,158,27,159],"BK Virus","Salivary Replication","Kidney Transplantation","DNAemia",[161,162,163,164,159],"BK virus","salivary replication","kidney transplantation","nephropathy","NOT_YET_RECRUITING","2025-12-02",{"date":168,"type":32},"2025-12-08",{"date":170,"type":21},"2025-12",{"date":172,"type":21},"2028-06",{"name":174,"class":39},"Centre Hospitalier Universitaire, Amiens",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100489679","apol1-genetic-testing-in-african-americans-100489679","NCT05656261","APOL1 Genetic Testing in African Americans","APOL1 Genetic Testing in African Americans: Exploring Attitudes About Genetic Risk to Improve Comprehensive Kidney Risk Assessment for Patients and Families","Inclusion Criteria:\n\n* Ages 18-90\n* Self-Identified as Black\u002FAfrican American. Race will be self-identified. Patients of African ancestry who identify as multi-racial are also eligible to participate.\n\nExclusion Criteria:\n\n* Cognitively impaired\u002Funable to provide consent\n* Terminally ill\n* Renal replacement therapy (RRT), e.g., (but not limited to) hemodialysis, peritoneal dialysis",true,"90 Years",{"count":185,"type":21},600,"Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient perceptions about knowledge of the results of APOL1 genetic testing, and how that impacts patient engagement with management of hypertension and other renal risk factors, is urgently needed.\n\n* In a Phase 1 pilot study, we offered APOL1 genetic testing to Black patients seen in our Hypertension and Nephrology clinics at Saint Louis University, an academic medical center that serves the local urban community, and surveyed patients on attitudes and concerns about APOL1 genetic testing. 144 participants were enrolled in Phase 1.\n* In the Phase 2 study, we will advance this important work in our community by offering participation to a broader patient base, including patients seen in Internal and Family Medicine clinics, SLU Hospital, as well as to first-degree relatives and spouses of SLUCare participants. This expansion seeks to advance understanding of environment-gene interactions, improve risk prediction, and target management of potentially modifiable risk factors.",[188,189,27,190,191],"Genetic Predisposition","Chronic Kidney Diseases","APOL1 Associated Kidney Disease","Disparities",[193],"APOL1 Renal Risk Variants","2025-03-17",{"date":196,"type":32},"2025-03-20",{"date":198,"type":32},"2019-01-24",{"date":200,"type":21},"2027-06-30",{"name":202,"class":39},"St. Louis University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100527397","phase-2-prevention-of-chronic-kidney-diseasecdk-progression-in-type-1-diabetes-with-long-term-use-of-sodium-glucose-cotransporter-inhibitors-avoiding-kidney-hypoxia-100527397","NCT06147232","Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia","Prevention of CKD Progression in Type 1 Diabetes With Long Term Use of SGLTi Avoiding Kidney hypOxia(PLUTO)","PLUTO","Inclusion Criteria:\n\n1. Persons ≥ 18 years of age with a diagnosis of type 1 diabetes (age at onset \\\u003C40 years; permanent insulin treatment initiated within 1 year of diagnosis)\n2. Albuminuria: UACR \\> 100 mg\u002Fg (in ≥2 out 3 morning spot urine collections prior to randomization)\n3. estimated Glomerular Filtration Rate(eGFR) ≥25 and \\\u003C 75 ml\u002Fmin\u002F1.73m2\n4. Participants must be on stable renin-angiotensin system blocking treatment 4 weeks before start of study drug and throughout study duration.\n5. Able to understand the written participant information and give informed consent\n\nExclusion Criteria:\n\n1. Non-diabetic kidney disease indicated by medical history and\u002For laboratory findings.\n2. eGFR\\\u003C 25 ml\u002Fmin\u002F1.73m2, dialysis or kidney transplantation.\n3. Previous diabetic ketoacidosis, except at debut.\n4. Dysregulated diabetes (HbA1c \\> 85 mmol\u002Fmol)\n5. Decreased awareness or unawareness\n6. Pregnancy, lactating or with a wish of pregnancy within the next year\n7. Low carbohydrate diet\n8. Receiving therapy with an SGLT inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT inhibitor.\n9. New York Heart Association (NYHA) class IV Congestive Heart Failure at the time of enrolment\n10. Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment\n11. The receipt of any investigational product 90 days prior to this trial\n12. Unable to participate in study procedures\n13. Any clinically significant disorder, except for conditions associated with type 1 diabetes, which in the Investigators opinion could interfere with the results of the trial\n14. Participation in another intervention study\n15. Exclusion criteria for MRI: known claustrophobia, known chronic lung disease, surgery within past 6 weeks or having foreign bodies of metal in the body (e.g. pacemaker, metal plates, metal screws)\n16. Recurrent urogenital infections.",{"count":212,"type":21},69,[214],"PHASE2","Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes. People with type 1 diabetes also have increased risk of cardiovascular and kidney disease, and may benefit from SGLT-inhibition. The exact mechanism of how SGLT-inhibition benefits the kidneys are yet unknown. Change in renal hypoxia may be a factor.\n\nObjective: The primary aim of this study is to assess the effects of 12 weeks SGLT-1 and 2 inhibition on renal oxygenation in persons with type 1 diabetes and chronic kidney disease.\n\nFurther aims are to study if renal oxygen consumption and response to SGLT-inhibition differs between people of African-Caribbean or Northern European decent.\n\nAdditionally effects on left ventricular ejection fraction, kidney function and biomarkers in blood and urine will be explored.\n\nMethod: 12 weeks treatment with oral sotagliflozin or matching placebo as intervention. Kidney oxygenation and perfusion parameters and left ventricular ejection fraction will be assessed by functional magnetic resonance imaging. Kidney function and biomarkers will be assessed according to local hospital laboratory guidelines.\n\nDesign: Randomized, double-blinded, placebo-controlled, cross over intervention study.\n\nStudy population: 69 persons with type 1 diabetes and diabetic kidney disease with albuminuria will be included, 39 at Steno Diabetes Center Copenhagen, 30 at King's College London.\n\nEndpoints: Primary end-point: Change from 0 to 12 weeks in dynamic R2\\*-weighted signal after treatment with sotagliflozin compared to placebo. Secondary endpoints: Change from 0 to 12 weeks with sotagliflozin compared with placebo on renal perfusion, renal artery flow, renal oxygen consumption, renal parenchymal triglyceride fraction, renal fibrosis, left ventricular ejection fraction, urinary albumin-creatinin ratio, ketone bodies, erythropoietin, pro brain natriuretic peptide, and plasma- and urine inflammation- and fibrosis biomarkers as well as difference after 12 weeks treatment in glomerular filtration rate.\n\nTimeframe: Inclusion of patients from february 2024. Last visit september 2025. Presentation spring 2026, publication fall 2026.",[27,217,218,219,220,221,222],"Diabetic Nephropathies","Diabetes Mellitus, Type 1","Albuminuria","Diabetic Complications Renal","Diabetic Complications Cardiovascular","Hypoxia","2025-01-22",{"date":225,"type":32},"2025-01-27",{"date":227,"type":21},"2025-02",{"date":229,"type":21},"2027-05",{"name":231,"class":39},"Steno Diabetes Center Copenhagen",2,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":165,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":40},"100554635","phase-4-sacubitrilvalsartan-treats-patients-with-essential-hypertension-and-type-2-diabetic-nephropathy-100554635","NCT06501651","Sacubitril\u002FValsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy","A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril\u002FValsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study","Hyper-Save","Inclusion Criteria:\n\n* Age 18 years or older, no gender restriction;\n* Diagnosed with mild to moderate primary hypertension (140 ≤ SBP \\\u003C 180 mmHg and\u002For 90 ≤ DBP \\\u003C 110 mmHg), including newly diagnosed or inadequately treated patients (those who have not followed previous medical advice and have uncontrolled blood pressure according to the investigator);\n* Diagnosed with type 2 diabetes (according to Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)), and meeting the following conditions: a) Continuously on ≥ 1 glucose control medication regimens (which may include long-acting insulin) for at least 12 weeks before screening, with a stable treatment regimen (i.e., the same medication and dosage) for at least 28 days before screening, and maintaining this regimen during the study. At the investigator's discretion, the dose of supplemental short-acting insulin can be adjusted as needed to achieve adequate glucose control; b) HbA1c level ≤ 10.5% and fasting (≥ 8 hours) plasma glucose level ≤ 13.3 mmol\u002FL (if fasting glucose \\> 13.3 mmol\u002FL, the investigator may repeat the test to determine eligibility);\n* Urine albumin\u002Fcreatinine ratio (UACR) ≥ 30 mg\u002Fg in two measurements taken on separate days or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²;\n* Non-pregnant or fertile patients (male or female) using reliable contraception;\n* Female patients with potential for pregnancy must have a negative pregnancy test at screening;\n* Subjects must voluntarily agree to comply strictly with the study protocol requirements and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Presence of severe hypertension, malignant hypertension, hypertensive emergencies, or hypertensive crises;\n* History or evidence of secondary hypertension within 12 months before screening, including but not limited to any of the following: renovascular hypertension, renal parenchymal hypertension, unilateral or bilateral renal artery stenosis, coarctation of the aorta, primary aldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension;\n* History of angioedema (drug-related or other causes) within 12 months before screening;\n* Presence of diabetic ketoacidosis;\n* History or evidence of secondary diabetes within 12 months before screening, including but not limited to any of the following: endocrine disorders causing carbohydrate metabolism disorders, pancreatogenic diabetes, hepatogenic diabetes, nephrogenic diabetes, etc.;\n* History of malignancy in any organ system (excluding localized basal cell carcinoma of the skin);\n* History of acute stroke, lacunar infarction, or dementia within 6 months before screening;\n* History of coronary artery bypass graft surgery or any percutaneous coronary intervention (PCI) within 6 months before screening;\n* Previously diagnosed or currently diagnosed heart failure (NYHA Class III-IV) or clinically significant valvular heart disease;\n* History or current diagnosis of cardiac abnormalities: (1) second or third-degree atrioventricular block without a pacemaker; (2) clinically significant arrhythmias, including atrial fibrillation with a ventricular rate ≥ 120 bpm; (3) family history of long QT syndrome or torsades de pointes ventricular tachycardia;\n* Chronic kidney disease stage 4 or higher (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²), receiving renal dialysis, or history of kidney transplantation;\n* Significant abnormalities in laboratory tests, such as potassium levels \\> 5.5 mmol\u002FL or \\\u003C 3.5 mmol\u002FL, sodium levels \\\u003C 130 mmol\u002FL, liver function (ALT, AST) results \\> 3 times the upper limit of normal;\n* History of allergy to antihypertensive drugs such as ARBs, Angiotensin-Converting Enzyme (ACE) inhibitors, or renin inhibitors;\n* Clear history of intolerance to drugs similar to the study medication (e.g., ACE inhibitors, ARBs);\n* Use of traditional Chinese or Western medicines that could affect the study's efficacy during the study period (see appendix for list);\n* Any surgery or medical condition that significantly alters the absorption, distribution, metabolism, or excretion of any medication, including but not limited to the following: clinically significant gastrointestinal surgery within 12 months before the screening (e.g., gastrectomy, gastrointestinal anastomosis, bowel resection, gastric bypass, gastroenterostomy, or gastric banding), current active inflammatory bowel disease or history of active inflammatory bowel disease;\n* Pregnant or breastfeeding women, or patients of childbearing potential unwilling or unable to use effective contraception during the study period;\n* Participation in another clinical study using any investigational drug or observational study within 30 days before screening;\n* Other conditions that, in the investigator's judgment, may affect the conduct of the clinical study or the determination of study results.",{"count":242,"type":21},297,[244],"PHASE4","This study aims to compare the efficacy and safety of Sacubitril\u002FValsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.",[247,54,27],"Essential Hypertension",[249,250,27,251],"Essential hypertension","Type 2 diabetes","Sacubitril\u002FValsartan","2024-07-09",{"date":254,"type":32},"2024-07-15",{"date":256,"type":21},"2024-08-01",{"date":258,"type":21},"2025-04-10",{"name":260,"class":39},"Sichuan Academy of Medical Sciences",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":276,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":40},"100503750","phase-4-effect-of-huaier-granule-on-the-treatment-of-idiopathic-membranous-nephropathy-100503750","NCT05839314","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled Study","Inclusion Criteria:\n\n* Renal biopsy was performed before randomization and pathologically diagnosed as idiopathic membranous nephropathy;\n* Anti-phospholipase a2 receptor (PLA2R) antibody is positive;\n* Aged from 18 to 75, either sex;\n* Tolerable doses of RASI were received for ≥4 weeks before randomization, nephrotic syndrome was not in remission and 24-hour urinary protein level was ≥3.5g\u002F24h and \\\u003C 8.0g\u002F24h;\n* The eGFR≥45ml\u002Fmin\u002F1.73m2 (Measured at least twice in 2 weeks);\n* The patient is willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed as secondary membranous nephropathy;\n* Rapidly progressive membranous nephropathy (eGFR decreased by 50 % compared with the baseline level within 3 months);\n* Receiving renal replacement therapy;\n* Diabetes and glycosylated hemoglobin (HbA1c) levels ≥ 7.0%;\n* Hypertension is not well controlled (systolic blood pressure\\>160mmHg or diastolic blood pressure\\>100mmHg);\n* The level of serum albumin≤20g\u002FL;\n* Resistance to treatment with CsA or other CNI, rituximab (RTX) or alkylating agents; complete remission or partial remission was obtained after treatment with CNI, RTX, or alkylating agents but there was a history of relapse within 3 months；\n* Suspected infection by imaging and\u002For laboratory tests;\n* Infectious diseases, such as hepatitis B, hepatitis C, AIDS, tuberculosis;\n* History of malignant tumor;\n* Hepatic dysfunction: aspartate aminotransferase (AST) concentration and alanine aminotransferase (ALT) concentration of \\> 1.5 × upper limit of normal;\n* Allergic to Huaier granule or Ciclosporin soft capsules;\n* Previous CNI treatment was ineffective;\n* Complicate with any diseases that may affect efficacy and safety evaluation;\n* Pregnant or lactating women, and patients (male or female) with fertility plans or unwilling to take effective contraceptive measures;\n* Participating in other clinical trials or participated in other clinical studies within 3 months;\n* According to the researchers, patients have diseases or conditions that increase the difficulty of enrollment or probability of loss to follow-up, such as mental illness, frequent changes in residence and work, etc.","75 Years",{"count":270,"type":21},480,[244],"This is a prospective, multicenter, randomized, open-label, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier granule on the treatment of idiopathic membranous nephropathy comparing with Ciclosporin soft capsules.",[27,274,275],"Glomerular Diseases","Idiopathic Membranous Nephropathy",[277,278,279],"Huaier granule","Ciclosporin","Idiopathic membranous nephropathy","2024-06-02",{"date":282,"type":32},"2024-06-04",{"date":284,"type":32},"2023-05-09",{"date":286,"type":21},"2027-07-01",{"name":288,"class":39},"Chinese PLA General Hospital",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":296,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":40},"100541069","the-role-of-renal-progenitors-and-polyploid-tubular-cell-response-in-glomerular-and-tubular-diseases-100541069","NCT06325059","The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases","Studying the Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases: Analysis on Renal Biopsies","Inclusion Criteria:\n\n* Patients with glomerular diseases undergoing renal biopsy (e.g., rapidly progressive glomerulonephritis, minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, lupus nephritis, membranous nephropathy, IgA nephropathy, etc)\n* Patients with AKI, regardless of the nature of the damage (septal, ischemic, toxic, or unknown).\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Sample insufficient and\u002For unavailable","1 Month","17 Years",{"count":110,"type":21},[153],"Renal progenitors are a subset of parietal epithelial cells (PECs) localized at the urinary pole of Bowman's capsule. Experimental models of podocyte damage showed that PECs can potentially regenerate lost podocytes by migrating from Bowman's capsule to the glomerular tuft, acquiring the morphological and functional features of mature podocytes. Podocyte loss and damage, as well as the inability of PECs to replace lost podocytes, lead to glomerular scarring and chronic kidney disease (CKD) progression.\n\nIn addition, the investigators of the present study and others have recently demonstrated the existence of a specific subpopulation of tubular cells in the human kidney with a high potential for regeneration and resistance to death, thus acting as tubular progenitors. These cells are involved in tubular response to damage during acute kidney injury (AKI) trough endoreplication (polyploidization).\n\nKidney biopsy is the cornerstone of diagnosis in many kidney diseases leading to CKD and AKI, allowing unambiguous diagnosis in some cases and presumptive diagnosis of ongoing disease in others. Very recently, super resolution imaging techniques proved to maintain current diagnostic standards while allowing to study morphological features of pathophysiological mechanisms of glomerular and tubular diseases.\n\nThe rationale of this project is to study the role of renal progenitors (PECs and tubular progenitors) in the pathogenesis of CKD and AKI trough super resolution imaging applied to human renal biopsies, to the aim of identifying relevant connections with clinical data and markers of damage and\u002For disease progression.",[27],"2024-03-15",{"date":304,"type":32},"2024-03-22",{"date":306,"type":32},"2023-03-22",{"date":308,"type":21},"2047-11-30",{"name":310,"class":39},"Meyer Children's Hospital IRCCS"]